JP7219224B2 - 乳癌の治療のための組合せ療法 - Google Patents

乳癌の治療のための組合せ療法 Download PDF

Info

Publication number
JP7219224B2
JP7219224B2 JP2019550800A JP2019550800A JP7219224B2 JP 7219224 B2 JP7219224 B2 JP 7219224B2 JP 2019550800 A JP2019550800 A JP 2019550800A JP 2019550800 A JP2019550800 A JP 2019550800A JP 7219224 B2 JP7219224 B2 JP 7219224B2
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutically acceptable
acceptable salt
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019550800A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510075A5 (https=
JP2020510075A (ja
Inventor
クレイグ ディー． カー，
マナフ コーパル，
ナタリー リウー，
ピーター ジェラード スミス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2020510075A publication Critical patent/JP2020510075A/ja
Publication of JP2020510075A5 publication Critical patent/JP2020510075A5/ja
Application granted granted Critical
Publication of JP7219224B2 publication Critical patent/JP7219224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019550800A 2017-03-16 2018-03-16 乳癌の治療のための組合せ療法 Active JP7219224B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472345P 2017-03-16 2017-03-16
US62/472,345 2017-03-16
PCT/US2018/022961 WO2018170447A1 (en) 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer

Publications (3)

Publication Number Publication Date
JP2020510075A JP2020510075A (ja) 2020-04-02
JP2020510075A5 JP2020510075A5 (https=) 2021-04-30
JP7219224B2 true JP7219224B2 (ja) 2023-02-07

Family

ID=61874039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550800A Active JP7219224B2 (ja) 2017-03-16 2018-03-16 乳癌の治療のための組合せ療法

Country Status (14)

Country Link
US (1) US11083722B2 (https=)
EP (2) EP3595725B1 (https=)
JP (1) JP7219224B2 (https=)
KR (1) KR102517650B1 (https=)
CN (1) CN110636862B (https=)
AU (1) AU2018234903B2 (https=)
BR (1) BR112019019261A2 (https=)
CA (1) CA3056701A1 (https=)
IL (1) IL269357B2 (https=)
MA (1) MA47776A (https=)
MX (1) MX2019010981A (https=)
RU (1) RU2764724C2 (https=)
SG (1) SG11201908531WA (https=)
WO (1) WO2018170447A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041986A1 (en) * 2016-11-28 2018-05-31 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
MX2020007312A (es) 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
JP2023548340A (ja) * 2020-11-06 2023-11-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳癌の治療方法
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176666A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer
US20160347717A1 (en) 2015-05-29 2016-12-01 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
CA2397593C (en) 2000-01-18 2009-11-10 Aventis Pharmaceuticals Inc. Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
ATE284400T1 (de) 2000-01-18 2004-12-15 Aventis Pharma Inc Ethanolsolvat von (-)-cis-2-(2-chlorphenyl)-5,7- dihydroxy-8- (4r-(3s-hydroxy-1- methyl)piperidinyl)-4h-1-benzopyran-4-on
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
KR20070107707A (ko) 2005-01-21 2007-11-07 아스텍스 테라퓨틱스 리미티드 피라졸 키나제 억제제와 추가 항종양제의 조합물
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
MX2007008781A (es) 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
US7776832B2 (en) 2006-04-21 2010-08-17 Gem Pharmaceuticals, Llc Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2008001101A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
WO2008007122A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
EP2049106A2 (en) 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
WO2008009954A1 (en) 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
WO2011130232A1 (en) 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
GB2483736B (en) * 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
KR102051881B1 (ko) 2010-10-25 2019-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
CN103703000B (zh) 2011-03-23 2015-11-25 安姆根有限公司 Cdk4/6和flt3的稠合三环双重抑制剂
AU2013352406A1 (en) 2012-11-28 2015-06-04 Novartis Ag Combination therapy
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
KR102529049B1 (ko) * 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
WO2016126889A1 (en) 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176666A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods of treating cancer
US20160347717A1 (en) 2015-05-29 2016-12-01 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Research， Vol.74, No.19,Supp.SUPPL.1，2014年，Abstract Number:4756
Cancer Research，2016年，Vol.76,No.11，pp.3307-3318
Cancer Research，2017年， Vol.77,No.4,Supp.Supplement 1，Abstract Number:OT2-01-07

Also Published As

Publication number Publication date
EP4218820A3 (en) 2023-09-20
IL269357B1 (en) 2024-06-01
EP3595725A1 (en) 2020-01-22
BR112019019261A2 (pt) 2020-06-16
IL269357B2 (en) 2024-10-01
SG11201908531WA (en) 2019-10-30
KR102517650B1 (ko) 2023-04-05
EP3595725B1 (en) 2023-05-03
MA47776A (fr) 2020-01-22
MX2019010981A (es) 2020-09-07
EP4218820A2 (en) 2023-08-02
CN110636862B (zh) 2026-03-20
AU2018234903B2 (en) 2024-02-08
CN110636862A (zh) 2019-12-31
IL269357A (en) 2019-11-28
KR20190125448A (ko) 2019-11-06
WO2018170447A1 (en) 2018-09-20
CA3056701A1 (en) 2018-09-20
JP2020510075A (ja) 2020-04-02
RU2764724C2 (ru) 2022-01-19
US20210113537A1 (en) 2021-04-22
RU2019132893A3 (https=) 2021-06-24
RU2019132893A (ru) 2021-04-16
AU2018234903A1 (en) 2019-10-10
US11083722B2 (en) 2021-08-10

Similar Documents

Publication Publication Date Title
JP7219224B2 (ja) 乳癌の治療のための組合せ療法
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
JP2019515010A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы
TW202416992A (zh) 雌激素受體降解劑之給藥方案

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230126

R150 Certificate of patent or registration of utility model

Ref document number: 7219224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250